PTO/SB/08a (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
				Application Number	10/591,923-Conf. #5393
INFORMATION DISCLOSURE				Filing Date	June 21, 2007
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Daniel J. Rader
				Art Unit	1614
	(Use as many sheets as necessary)			Examiner Name	K. E. Weddington
Sheet	1	of	3	Attorney Docket Number	AGP-002

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/K.W	∫A1*	US-4,716,175	12-29-1987	Hoefle et al.	
8	A2*	US-5,015,644	05-14-1991	Roth et al.	
	A3*	US-5,026,554	06-25-1991	Bartizal et al.	
***************************************	A4*	US-5,510,379	04-23-1996	Lee et al.	
	A5*	US-6,121,283	09-19-2000	Chang et al.	
80	A6*	US-6,140,343	10-31-2000	DeNinno et al.	
	A7*	US-7,358,254	04-15-2008	Robl et al.	
	A8*	US-7,394,501	07-01-2008	Iwata et al.	
	A9*	US-2003/0153541	08-14-2003	Dudley et al.	
	A10*	US-2006/0160834	07-20-2006	Fong et al.	
	A11*	US-2006/0166999	07-27-2006	Grutzmann et al.	
	A12*	US-2007/0098778	05-03-2007	Borsadia	
	A13*	US-2007/0099884	05-03-2007	Erondu et al.	
	A14*	US-2008/0016127	01-17-2008	Field	
	A15*	US-2008/0033019	02-07-2008	Stamler	
	A16*	US-2008/0051427	02-28-2008	Schuckler	
\square	A17*	US-2008/0103122	05-01-2008	Veltri	
*	A18*	US-2008/0161279	07-03-2008	Wisler	
/K.W	/A19*	US-2008/0175864	07-24-2008	Ye et al.	

	FOREIGN PATENT DOCUMENTS					
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No. ¹	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	
/K.W./	B1	WO-96/026948-A1	09-06-1996	Pharmacia Spa et al.		
жене	B2	WO-05/033100-A1	04-14-2005	Lipideon Biotechnology Ag et al.		
00000	ВЗ	WO-07/047724	04-26-2007	Wisler		
	B4	WO-08/012056	01-31-2008	Zeiss Carl Microimaging		
W	B5	WO-08/021353	02-21-2008	Luo Guangxiang		
/K.W./	B6	WO-08/030382	03-13-2008	Schering Corp		П

Examiner	/Kevin Weddington/	Date	07/00/0040
Signature	/Neviii weddiiglaii/	Considered	07/20/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filled after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 07/31/2012, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO 10/591,923-Conf. #5393 Application Number June 21, 2007 INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor Daniel J. Rader Art Unit 1614 (Use as many sheets as necessary) Examiner Name K. E. Weddington Sheet 2 3 AGP-002 of Attorney Docket Number

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/K W /	A20*	US-2008/0241869	10-02-2008	Davis	
8	A21*	US-2008/0248070	10-09-2008	Tunac	
8	A22*	US-2008/0253985	10-16-2008	Wisler	
	A23*	US-2008/0255084	10-16-2008	Webb	
ů	A24*	US-2008/0280992	11-13-2008	Kunz et al.	
	A25*	US-2009/0042835	02-12-2009	Davis	
	A26*	US-2009/0042941	02-12-2009	Rader	
\square	A27*	US-2009/0054393	02-26-2009	Wisler	
*	A28*	US-2009/0093527	04-09-2009	Li et al.	
/K.W./	A29*	US-7,645,732	01-12-2010	Ye et al.	

		FOREI	GN PATENT	DOCUMENTS		
Examiner Cite Initials* No.1		Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document		T^6
/K.W./	B7	WO-08/072061	06-19-2008	Pfizer Prod Inc.		
š	B8	WO-08/075949	06-26-2008	Stichting Top Inst		
lacksquare	В9	WO-08/079398-A1	07-03-2008	Aegerion Pharmaceuticals Incet al.		
W	B10	WO-08/090198	07-31-2008	Janssen Pharmaceutica NV		
/K W /	B11	WO-08/115574	09-25-2008	Reliant Pharmaceuticals, Inc.		
1						

Examiner		Date	07/00/0040
Signature	/Kevin Weddinaton/	Considered	07/20/2010

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/591,923-Conf. #5393	
IN.	NFORMATION	1 DI	SCLOSURE	Filing Date	June 21, 2007	
S	STATEMENT BY APPLICANT			First Named Inventor	Daniel J. Rader	
				Art Unit	1614	
	(Use as many sheets as necessary)			Examiner Name	K. E. Weddington	
Sheet	3	of	3	Attorney Docket Number	AGP-002	

xaminer nitials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<.W./	C1	Aggarwal, et al; BMC Cardiovasc. Disord. 27;5(1):30 (2005)	
2000	C2	Chandler, et al., J. Lipid. Res. 44(10):1887-901 (2003)	
C3 C4		Cuchel et al., "Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia," N Engl J Med., (2007); 356:148-156.	
		Funatsu et al. "Atorvastatin Increases Hepatic Fatty Acid Beta-Oxidation in Sucrose-Fed Rats: Comparison with an MTP Inhibitor." Eur. J. Pharm. 2002 455:161-167	
	C5	Li, et al., "Discovery of Potent and Orally Active MTP Inhibitors as Potential Anti-Obesity Agents," Bioorganic & Medicinal Chemistry Letters, Oxford, GB, Vol. 16, No. 11, 1 June 2006, pp. 3039-3042	
20000000000000000000000000000000000000	C6	Looije, Norbert A., et al., "Disodium Ascorbyl Phytostanyl Phosphates (FM-VP4) Reduces Plasma Cholesterol Concentration, Body Weight and Abdominal Fat Gain Within a Dietary-Induced Obese Mouse Model," Journal of Pharmacy & Pharmaceutical Sciences: A Publication of the Canadian Society for Pharmaceutical Sciences, Vol. 8, No. 3, 2005, pp. 400-408	
/K.W./	C7	Samaha, et al., "Inhibition Of Microsomal Triglyceride Transfer Protein Alone Or With Ezetimibe In Patients With Moderate Hypercholesterolemia," Nature Clinical Practice, (2008), pp. 1-9, Nature Publishing Group	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.